MedPath

Clinical Trial News

Rare RAD51C Mutation Unlocks Immunotherapy Success in Pancreatic Cancer Patient

  • A patient with stage IV pancreatic cancer experienced an unprecedented recovery due to a rare RAD51C mutation identified through PanCAN's Know Your Tumor program.
  • The patient's oncologist, Dr. Peter Hosein, used an off-label immunotherapy combination after chemotherapy failed, leading to dramatic tumor shrinkage and improved health.
  • Research is now focused on understanding how immunotherapy works in patients with RAD51C mutations to potentially extend benefits to a broader pancreatic cancer population.
  • This case highlights the importance of genetic and biomarker testing in pancreatic cancer to identify personalized treatment options and improve survival rates.

Hyperbaric Oxygen Therapy Evaluated for Ulcerative Colitis Treatment in Clinical Trial

  • A clinical trial is underway at the University of Miami Miller School of Medicine, among 15 sites, to assess hyperbaric oxygen therapy (HBOT) for ulcerative colitis treatment.
  • The study explores HBOT's potential to reduce inflammation and improve outcomes in ulcerative colitis patients by increasing oxygen delivery to the colon.
  • Researchers aim to determine if HBOT, as an adjunctive treatment, can lessen the need for surgery and improve inflammation during ulcerative colitis flare-ups.
  • The trial involves randomizing hospitalized ulcerative colitis patients receiving intravenous steroids to either HBOT or a control group to measure treatment impact.

Summit Therapeutics' Ivonescimab Outperforms Keytruda in Lung Cancer Trial

  • Summit Therapeutics announced that its investigational bispecific antibody, ivonescimab, demonstrated superior efficacy compared to Merck's Keytruda in a clinical trial for non-small cell lung cancer.
  • The trial results mark a significant milestone for Summit Therapeutics and its CEO, Robert Duggan, potentially disrupting the competitive landscape of lung cancer treatments.
  • Ivonescimab's success could offer a new treatment option for patients with non-small cell lung cancer, addressing a major market for cancer therapeutics.
  • Robert Duggan, known for his unconventional approach to the pharmaceutical industry, has once again led a company to a major breakthrough, challenging established norms.

Corvus Pharmaceuticals Launches Phase 3 Trial of Soquelitinib for Relapsed/Refractory PTCL

  • Corvus Pharmaceuticals has initiated a Phase 3 clinical trial for soquelitinib in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).
  • The trial is a randomized, controlled study comparing soquelitinib to standard of care chemotherapy, aiming to enroll approximately 150 patients across multiple global sites.
  • Soquelitinib, a first-in-class ITK inhibitor, has shown durable anti-tumor activity and a novel mechanism of action enhancing the host anti-tumor response in earlier trials.
  • The primary endpoint of the trial is progression-free survival, with secondary endpoints including overall survival and objective response rate.

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048RecruitingPhase 3
Corvus Pharmaceuticals, Inc.
Posted 10/2/2024

Sotagliflozin Improves Glycemic Control in Type 2 Diabetes Patients on Insulin Therapy

  • A secondary analysis of the SOTA-INS CGM Phase 3 trial reveals that sotagliflozin significantly improves time-in-range (TIR) for type 2 diabetes patients on insulin.
  • The study demonstrated that sotagliflozin, at 400 mg daily, enhances glucose variability and other CGM parameters in insulin-treated T2D patients.
  • Sotagliflozin (200 mg and 400 mg) approached the American Diabetes Association's TIR target of at least 70% (17 hours) in T2D patients.
  • These findings support the potential of SGLT1 inhibition as a therapeutic strategy to improve glycemic control in type 2 diabetes, according to researchers.

Zongertinib Shows Promise in HER2-Mutated NSCLC: Boehringer Ingelheim Reports Positive Phase Ib Results

  • Boehringer Ingelheim's zongertinib demonstrated a 66.7% objective response rate in HER2-mutated NSCLC patients previously treated, showcasing potential efficacy.
  • The Beamion LUNG-1 trial indicated that zongertinib is well-tolerated, with tumor shrinkage observed in a significant portion of patients across tested doses.
  • Zongertinib may offer activity against brain metastases, addressing a critical unmet need in non-small cell lung cancer treatment, according to initial data.
  • The 120mg dose of zongertinib was selected for further evaluation after an interim analysis, aiming to optimize efficacy and safety in future trials.

Radiopathomics Model Predicts Progression-Free Survival in Nasopharyngeal Carcinoma

  • An integrative radiopathomics model, combining radiomics, pathomics, and clinical factors, shows promise in predicting progression-free survival (PFS) for nasopharyngeal carcinoma (NPC) patients.
  • The model utilizes MRI and whole-slide imaging (WSI) to extract predictive features, enhancing risk stratification and treatment planning for NPC.
  • The radiopathomics model demonstrated superior performance compared to radiomics, pathomics, or clinical models alone, as validated through concordance index and calibration curve analyses.
  • This approach offers a non-invasive method to improve prognostic assessment and personalize treatment strategies in NPC, potentially improving patient outcomes.

NHS Scotland Approves Elranatamab and Teclistamab for Relapsed/Refractory Multiple Myeloma

  • Elranatamab and teclistamab, bispecific antibodies, have been approved by NHS Scotland for myeloma patients who have undergone at least three prior treatments.
  • Clinical trials show these drugs can halt myeloma progression for an average of 11 months and induce complete remission in some patients who previously did not respond to treatment.
  • These treatments represent the first new class of myeloma drugs approved in Scotland in nearly seven years, offering a new lifeline for patients with limited options.
  • The approvals are based on data from the MajesTEC-1 and MagnetisMM-3 trials, demonstrating overall response rates of 63% and 61% for teclistamab and elranatamab, respectively.

Sulthiame Shows Promise in Reducing Obstructive Sleep Apnea Symptoms

  • A clinical trial presented at the European Respiratory Society Congress 2024 suggests sulthiame, an epilepsy drug, reduces sleep apnea symptoms.
  • Patients taking sulthiame experienced fewer breathing interruptions during sleep and improved blood oxygen levels compared to placebo.
  • The study involved nearly 300 participants with OSA who could not tolerate CPAP machines, showing a potential alternative treatment.
  • Further trials are needed to confirm these benefits before sulthiame can be widely adopted as a treatment for sleep apnea.

Halia Therapeutics Presents Phase II Data on HT-6184 for Post-Procedural Inflammation and Pain

  • Halia Therapeutics presented Phase II clinical trial data for HT-6184, an oral NEK7/NLRP3 inhibitor, at the 6th Inflammasome Therapeutics Summit.
  • The study (NCT06241742) evaluated HT-6184's efficacy in reducing post-procedural inflammation and pain following third molar extraction.
  • HT-6184 targets the NLRP3 inflammasome, aiming to improve outcomes in inflammatory and neurodegenerative diseases by inhibiting IL-1β and IL-18 release.
  • The presentation highlighted innovative endpoints for measuring therapeutic benefit in inflammatory-induced pain, offering time-effective assessments.

Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction

NCT06241742CompletedPhase 2
Halia Therapeutics, Inc.
Posted 2/12/2024

Study to Evaluate HT-6184 in Healthy Subjects

NCT05447546CompletedPhase 1
Halia Therapeutics, Inc.
Posted 6/15/2022

Trending News

1

Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Advance One-Time Gene Editing Treatments for Cardiovascular Disease

5 days ago
2

Eli Lilly Acquires Gene-Editing Biotech Verve Therapeutics for $1.3 Billion to Expand Cholesterol Treatment Pipeline

5 days ago
3

AbbVie's VERONA Trial for High-Risk Myelodysplastic Syndrome Fails to Meet Primary Survival Endpoint

6 days ago
4

FDA Approves CSL's ANDEMBRY for Hereditary Angioedema Prevention with Novel Factor XIIa Targeting

6 days ago
5

FDA Approves Tafasitamab Triple Combination for Relapsed/Refractory Follicular Lymphoma

4 days ago
6

Samsung Biologics Expands Into Preclinical Research with Launch of Samsung Organoids Drug Screening Platform

7 days ago
7

AbbVie's Atogepant Demonstrates Superior Tolerability and Efficacy Over Topiramate in Phase 3 Migraine Prevention Trial

4 days ago
8

D&D Pharmatech's DD01 Shows Rapid Liver Fat Reduction in MASH Phase 2 Trial, Matching Competitor Results in Quarter of the Time

6 days ago
9

Draig Therapeutics Emerges from Stealth with $140M to Advance Novel Neuropsychiatric Therapies

4 days ago
10

NHS App to Feature Clinical Trial Matching System as UK Targets 150-Day Setup Times

7 days ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy